Citigroup Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 61.1%

Neg 61.1% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from $17 to $16.